Synairgen announces results of in vitro studies showing antiviral activity of interferon-beta against key SARS-CoV-2 variants
Synairgen plc (SNG.L) Full Year Results/Significant progress continues towards a treatment for COVID-19
Preliminary results for the year ended 31 December 2020